Premium
Chronic resveratrol treatment alleviates myocardial ischemia injury in a hypertensive model
Author(s) -
Durham Kristina K,
Smith Chris S,
Rush James WE
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.25.1_supplement.639.11
Resveratrol, a polyphenol and natural antioxidant present in grapes and wine, acts as a cardioprotective agent and can be used to precondition the heart. Clinical and experimental studies show that hypertension increases susceptibility to ischemic injury. In the present study we explored the effects of chronic resveratrol treatment on postischemic myocardial function in a hypertensive model using adult spontaneously hypertensive rats (SHR) and normotensive Wistar Kyoto rats (WKY). Rats ingested either a high dose (H) of 2.7mg/day, low dose (L) of 0.027mg/day, or no resveratrol in drinking water for 28 days, at which point hearts were excised and mounted on a Langendorff apparatus. Once stable conditions were established all hearts were subjected to 30 minutes of no flow ischemia followed by 2 hours of reperfusion. Left ventricular developed pressure was significantly improved 2 hours post ischemia in both H and L groups of SHR compared to controls (86.5±1.6% and 88.1±7% vs.66.1±10%, p<.01) and in H group of WKY (75±15% vs. 57±6.7%, p<.05). A higher rate of pressure development was maintained in H groups compared to controls of both SHR (3993.8±553mmHg/s vs 2947.5±783mmHg/s p<.05) and WKY (3285.1±451mmHg/s vs. 2293.2±506mmHg/s p<.01). These results indicate that chronic resveratrol plays a cardioprotective role in an adult hypertensive rat model. Supported by HSFO and NSERC.